11 April 2019

Renal or hepatic impairment is a common comorbidity for patients with cancer either because of the disease itself, toxicity of previous anticancer treatments, or because of other factors affecting organ function, such as increased age.

Because renal and hepatic function are among the main determinants of drug exposure, the pharmacokinetic profile might be altered for patients with cancer who have renal or hepatic impairment, necessitating dose adjustments. Most anticancer drugs are dosed near their maximum tolerated dose and are characterised by a narrow therapeutic index. Consequently, selecting an adequate dose for patients who have either hepatic or renal impairment, or both, is challenging and definitive recommendations on dose adjustments are scarce.

In the Lancet Oncology, Raboudumc researchers from the department of Pharmacy (Stefanie Krens, Nielka van Erp, David Burger) and the department of Medical oncology (Gerben Lassche, Ingrid Desar, Carla van Herpen) wrote a comprehensive review in which they discuss the effect of renal and hepatic impairment on the pharmacokinetics of anticancer drugs. To guide clinicians in selecting appropriate dose adjustments, information from available drug labels and from the published literature were combined to provide a practical set of recommendations for dose adjustments of 160 anticancer drugs for patients with hepatic and renal impairment.

See publication in Lancet Oncology
 

Related news items


KWF Roadshow 11 November 2019

10 October 2019

In which way(s) can KWF provide optimal support to oncological research and care? How can we maximize impact on our investments? These questions are pivotal in Ambition 2030: the vision that KWF developed in close cooperation with stakeholders in the oncological field.

read more

More than 3000 visitors at Open Day RIHS

10 October 2019

On Sunday 6 October RIHS organized an Open Day in the Weekend of Science (“Weekend van de Wetenschap”) with special guest and television presenter Klaas van Kruistum. More than 3000 visitors became a health scientist for one day and discovered how special healthcare research is.

read more

Dorine Swinkels collaborates with winners of the Nobel Prize in Physiology or Medicine

9 October 2019

The Nobel Prize in Physiology or Medicine 2019 was awarded jointly to William G. Kaelin Jr, Sir Peter J. Ratcliffe and Gregg L. Semenza for their discoveries of how cells sense and adapt to oxygen availability.

read more

Scaling up nanotherapy

7 October 2019

Scaling up and translating nanotherapy from pre-clinical work in small animal models to a clinical application is not trivial. Raphael Duivenvoorden, theme Renal disorders, and colleagues, published their results on translating a new nanoimmunotherapy in the journal Science Translational Medicine.

read more

Jubilee lecture and symposium Carl Figdor

3 October 2019

For Carl Figdor, theme Cancer development and immune defense, who has been active in the field of tumor immunology for 40 years, a jubilee lecture and symposium will be organised. 

read more

‘Smart shirt’ can accurately measure breathing and could be used to monitor lung disease

3 October 2019

Denise Mannée and colleagues are developing Hexoskin, a smart shirt that can measure breathing in people. It can reliably measure breathing in healthy people while carrying out activities. This means they can now test out the smart shirts with patients who have COPD.

read more